On the upside
According to Bloomberg, China's Minsheng Bank plans to increase its stake in UCBH Holdings (Nasdaq: UCBH) from its current 9.6% to at least 50%.
Labopharm's (Nasdaq: DDSS) active pharmaceutical ingredient supplier resolved manufacturing deficiencies with the Food and Drug Administration.
Goldman Sachs analyst Steven Kent upgraded Wyndham Worldwide (NYSE: WYN) for the company's decision to focus on its fee-for-service business rather than a timeshare business.
On the downside
Viasystems Group announced an all stock deal to purchase rival Merix (Nasdaq: MERX).
Gammon Gold (NYSE: GRS) announced a bought deal financing agreement for $100 million.
AspenBio Pharma (Nasdaq: APPY) priced its offering of 4.5 million shares of common stock at $1.70 per share.
In the broad market, declining issues outpaced advancers by a margin of more than 5 to 4 on the NYSE and by 9 to 7 on Nasdaq. The Russell 2000 which tracks small cap stocks eased a point to 600.
